Charu Aggarwal, MD, MPH

Charu Aggarwal, MD, MPH, is a physician leader in Airways Malignancies Research, director of Precision Oncology Innovation at Penn Center for Cancer Care Innovation, section chief of Head & Neck and Thoracic Cancers, Hematology-Oncology, and the Leslye M. Heisler Professor for Lung Cancer Excellence at Penn Medicine in Philadelphia, Pennsylvania.

Articles

Navigating Uncommon EGFR Mutations in NSCLC: Challenges and Insights

December 13th 2023

Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.

Advancements in Targeted Therapy for Metastatic NSCLC

December 11th 2023

Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.

Metastatic NSCLC: Key Challenges in Molecular Testing and Treatment Access

December 11th 2023

Explore the complexities of limited molecular genotyping availability, the importance of comprehensive testing, and challenges in accessing target therapies, including cost considerations, in real-world clinical practice.

Standard-of-Care Approaches in EGFR-Mutant NSCLC

December 6th 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

Navigating Uncommon Mutations in NSCLC Treatment Decisions

December 6th 2023

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

Barriers in Concurrent Testing for mNSCLC: Real-world Challenges and Solutions

December 4th 2023

Experts reflect on the mixed enthusiasm for concurrent liquid and tissue testing, addressing insurance coverage concerns and the importance of shortening turnaround time, while highlighting efforts to make comprehensive testing the default in the community.

Impact of Molecular Testing on Lung Cancer Survival: Real-world Insights

December 4th 2023

A comprehensive study on the association between the availability of molecular genotyping results and overall survival in advanced non-squamous, non-small cell lung cancer patients, shedding light on the importance of timely and concurrent testing.

Non–Small Cell Lung Cancer: Streamlining Turnaround Times in Biomarker Testing

November 29th 2023

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

Available Methods for Biomarker Testing in Non–Small Cell Lung Cancer

November 29th 2023

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

Decoding Lung Cancer Mutations: Navigating Molecular Profiling in Practice

November 27th 2023

Key opinion leaders Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, reflect on their institution’s practices with regard to molecular profiling and its impact on treatment pathways in the setting of metastatic NSCLC.

Identifying Key Molecular Targets in Metastatic NSCLC

November 27th 2023

Shared insight into the comprehensive list of molecular targets in metastatic NSCLC, from point mutations like EGFR and KRAS to fusions such as ALK and ROS1, understanding the challenges of comprehensive testing and treatment implications.

Patient Scenario: Navigating Molecular Testing Dilemmas in Metastatic NSCLC

November 20th 2023

Experts review a patient scenario of metastatic non-squamous NSCLC and discuss complexities and challenges of initiating timely molecular testing, examining its impact on treatment decisions and patient outcomes.

Advancements in Precision Oncology: Metastatic NSCLC Treatment Landscape

November 20th 2023

Explore the dynamic landscape of metastatic non-squamous non-small cell lung cancer treatment, focusing on molecular genotyping, targeted therapies, and the evolving standard of care.

Clinical Practice Pearls and the Future of SCLC

August 11th 2022

The panel shares clinical pearls for community oncologists treating small cell lung cancer.

Investigational Agents in SCLC in the Second Line Setting and Beyond

August 11th 2022

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

August 11th 2022

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

August 2nd 2022

Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.

Lurbinectedin for SCLC Treatment in the Second-Line Setting

August 2nd 2022

Dr Vivek Subbiah explains the clinical trial data that led to the approval of lurbinectedin for SCLC treatment.

Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

July 29th 2022

The panel discusses the second line treatment options in SCLC and how they choose among the various options based on patient and disease characteristics.

Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

July 29th 2022

Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.